Your browser doesn't support javascript.
loading
Better safe than sorry: dual targeting antibodies for cancer immunotherapy.
Schoenfeld, Katrin; Harwardt, Julia; Kolmar, Harald.
Affiliation
  • Schoenfeld K; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Strasse 4, D-64287 Darmstadt, Germany.
  • Harwardt J; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Strasse 4, D-64287 Darmstadt, Germany.
  • Kolmar H; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Strasse 4, D-64287 Darmstadt, Germany.
Biol Chem ; 405(7-8): 443-459, 2024 Jul 26.
Article in En | MEDLINE | ID: mdl-38297991
ABSTRACT
Antibody-based therapies are revolutionizing cancer treatment and experience a steady increase from preclinical and clinical pipelines to market share. While the clinical success of monoclonal antibodies is frequently limited by low response rates, treatment resistance and various other factors, multispecific antibodies open up new prospects by addressing tumor complexity as well as immune response actuation potently improving safety and efficacy. Novel antibody approaches involve simultaneous binding of two antigens on one cell implying increased specificity and reduced tumor escape for dual tumor-associated antigen targeting and enhanced and durable cytotoxic effects for dual immune cell-related antigen targeting. This article reviews antibody and cell-based therapeutics for oncology with intrinsic dual targeting of either tumor cells or immune cells. As revealed in various preclinical studies and clinical trials, dual targeting molecules are promising candidates constituting the next generation of antibody drugs for fighting cancer.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Neoplasms Limits: Animals / Humans Language: En Journal: Biol Chem Journal subject: BIOQUIMICA Year: 2024 Document type: Article Affiliation country: Germany Country of publication: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Neoplasms Limits: Animals / Humans Language: En Journal: Biol Chem Journal subject: BIOQUIMICA Year: 2024 Document type: Article Affiliation country: Germany Country of publication: Germany